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Introduction: Recent oral contraceptive (OC) use has been consistently associated with increased risk of breast
cancer, but evidence on specific breast cancer subtypes is sparse.
Methods: We investigated recency and duration of OC use in relation to molecular subtypes of breast cancer in a
pooled analysis of data from the African American Breast Cancer Epidemiology and Risk Consortium. The study
included 1,848 women with estrogen receptor-positive (ER+) breast cancer, 1,043 with ER-negative (ER-) breast
cancer (including 494 triple negative (TN) tumors, which do not have receptors for estrogen, progesterone, and
human epidermal growth factor 2), and 10,044 controls. Multivariable polytomous logistic regression models were
used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for exposure categories relative to never use,
controlling for potential confounding variables.
Results: OC use within the previous 5 years was associated with increased risk of ER+ (OR 1.46, 95% CI 1.18 to 1.81),
ER- (OR 1.57, 95% CI 1.22 to 1.43), and TN (OR 1.78, 95% CI 1.25 to 2.53) breast cancer. The risk declined after
cessation of use but was apparent for ER+ cancer for 15 to 19 years after cessation and for ER- breast cancer for an
even longer interval after cessation. Long duration of use was also associated with increased risk of each subtype,
particularly ER-.
Conclusions: Our results suggest that OC use, particularly recent use of long duration, is associated with an
increased risk of ER+, ER-, and TN breast cancer in African American women. Research into mechanisms that explain
these findings, especially the association with ER- breast cancer, is needed.Introduction
A combined analysis of 54 studies observed a 24%
increase in breast cancer risk for current use of oral con-
traceptives (OCs) and a 16% increase in risk for <5 years
since stopping OC use [1]; the increase largely disap-
peared within 10 years after cessation. However, the
length of time during which risk remains elevated is un-
certain because few studies have assessed long intervals
since stopping [2,3]. Subsequent studies suggest that* Correspondence: tnb@bu.edu
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unless otherwise stated.long duration of OC use may also increase incident
breast cancer risk [4-13]. These studies were based pri-
marily on data from White women.
Gene expression studies have identified at least five in-
trinsic subtypes of breast cancer, and the most common
clinical markers of breast cancer heterogeneity to date
have been presence or absence of estrogen receptors
(ERs) or progesterone receptors (PRs) and overexpres-
sion of human epidermal growth factor receptor 2
(HER2) [14]. Tumors that are ER– or triple negative
(TN, defined as ER–/PR–/HER2–) have a lower 5-year
survival than ER+ tumors [15,16], and are more commonThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ancestry [17-19].
Some risk factors, particularly hormone-related factors,
appear to differentially associate with specific breast can-
cer subtype [20,21], but evidence on OC use in relation to
specific breast cancer subtypes is sparse and the findings
are inconsistent [22]. Some studies find OC use to be as-
sociated with increased risk of ER+ and ER– breast cancer
[4,9], others with increased risk of ER– breast cancer only
[23], and yet others observe an association solely for
ER+ breast cancer [24]. With respect to TN breast cancer,
null results [2,25] and an increased risk [23,26] have been
observed for OC use.
The objective of the present study was to investigate
OC use in relation to molecular subtypes of breast
cancer in African American women using data from a
large consortium, the African American Breast Cancer
Epidemiology and Risk (AMBER) project. In particular,
we were able to assess long duration of OC use and re-
cency of use, including intervals as long as 30 years or
more since last use.
Methods
Participating studies and data collection
The AMBER Consortium has been described in detail
elsewhere [27]. Its purpose is to provide enough data
and samples for informative assessment of genetic and
nongenetic factors in relation to breast cancer subtypes
in African American women. The AMBER Consortium
pools data from two large case–control studies, the
Carolina Breast Cancer Study (CBCS) and the Women’s
Circle of Health Study (WCHS), and two large cohort
studies, the Black Women’s Health Study (BWHS) and
the Multiethnic Cohort Study. Owing to missing data on
recency of OC use, the Multiethnic Cohort Study was
not included in this analysis, whereas data from the
BWHS, the CBCS, and the WCHS were included.
The BWHS is a prospective cohort study of 59,000
African American women aged 21 to 69 years at baseline
in 1995 [28]. Participants report data on OC use, other
risk factors, and incident disease on biennial question-
naires. Questionnaire follow-up is complete for 80% of
the baseline cohort through 2011. New diagnoses of can-
cer are self-reported on the follow-up questionnaires or
identified through linkage with state cancer registries
[9,27]. For each case, controls were selected from the
pool of BWHS participants who had not developed
breast cancer at the date of the case’s breast cancer diag-
nosis (index date). Controls were frequency-matched to
cases on 5-year age group, geographic region, and most
recent questionnaire completed before the matched case
diagnosis. Exposure and covariate data from that ques-
tionnaire and preceding questionnaires were used for
the analysis.The CBCS is a population-based case–control study of
women aged 20 to 74 years in North Carolina conducted
from 1993 through 2001 [29]. Breast cancer cases are
identified through the North Carolina Central Cancer
Registry. We used data from the first two phases, in
which younger and African American cases were over-
sampled. Cases and controls were sampled using a
modification of randomized recruitment. Controls youn-
ger than age 65 years were identified from Division of
Motor Vehicle lists and controls age 65 years or older
were identified from Health Care Financing Administra-
tion lists. Controls were frequency-matched to cases on
age in 5-year age groups. Exposure and covariate data
were collected through in-person interviews with refe-
rence to the year before diagnosis (cases) or interview
date (controls) [29]. Response rates were 76% for cases
and 55% controls for recruitment of invasive breast can-
cer cases and matched controls, while response rates
were 83% for cases and 65% controls for recruitment of
in situ breast cancer cases and matched controls [29].
The WCHS is a population-based case–control study
of women aged 20 to 75 years that began in New York
in 2003 and currently enrolls participants in New Jersey
only [30,31]. Breast cancer cases were identified through
major hospitals in New York City and through the New
Jersey Cancer Registry. Controls were identified through
random digit dialing and through community-based re-
cruitment and are frequency matched to cases on age in
5-year age groups [31]. Exposure and covariate data were
collected through in-person interviews with reference
to the year before diagnosis (cases) or interview date
(controls) [30]. Response rates were 78.7% in cases and
48.2% in controls [32].
Each study obtained informed consent from all par-
ticipants and was approved by the relevant Institutional
Review Boards, which are listed in Acknowledgements.
Each study prepared a data file that included question-
naire data for a specified set of variables and pathology
data from medical records or state cancer registry re-
cords. Data were harmonized at the data coordinating
center with regular input from each study’s principal in-
vestigator and data collection staff.
Cases
Incident cases of breast cancer (primary site codes C500
to C506, C508, and C509 in the International Clas-
sification of Diseases for Oncology, Third Edition), not
including lobular carcinoma in situ (8520/2), phyllodes tu-
mors (9020), or Paget’s disease (8540/3), were confirmed
through medical records and state cancer registries [33].
Immunohistochemistry results were obtained from hos-
pital pathology records and cancer registry data, and were
used to classify cases as ER+, ER–, and TN (ER–/PR–/
HER2–). ER data were available for 72% of cases and PR
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become routine more recently; therefore, HER2 data were
available for only 49% of cases. There were no statistically
significant differences between women with and without
known receptor status by age or OC use. The proportion
of ER– cases (Table 1) are similar to those observed for
African American women in other data sources [34-36].
Exposure variables
Oral contraceptive use
The main exposures of interest for the present analyses
were self-reported recency of OC use (years since last
use) and duration of OC use. Women with a total dura-
tion of OC use of less than 1 year were considered to be
never users. Recency of OC use was categorized asTable 1 Characteristics of cases and controls in the AMBER Co
BWHS CBCS
Cases Controls Cases C
Characteristics of breast cancer cases
Total 1,313 804
ER+ 862 (66) 436 (54)
ER– 451 (34) 368 (46)
Triple negative 155 (12) 210 (26)
Age at diagnosis
< 40 years 98 (8) 129 (16)
40 to 49 years 385 (29) 262 (33)
50 to 59 years 456 (35) 190 (24)
≥ 60 years 374 (29) 223 (28)
Oral contraceptive use among cases and controls
Ever use
No 525 (40) 3,768 (45) 392 (49) 3
Yes 788 (60) 4,522 (55) 412 (51) 3
Recency of OC use
< 5 years ago 182 (14) 950 (11) 68 (8) 5
5 to 9 years ago 68 (5) 464 (6) 44 (5) 3
10 to 14 years ago 77 (6) 499 (6) 53 (7) 5
15 to 19 years ago 105 (8) 620 (7) 95 (12) 8
20 to 24 years ago 108 (8) 692 (8) 90 (11) 1
25 to 29 years ago 124 (9) 653 (8) 35 (4) 4
≥ 30 years ago 124 (9) 644 (8) 24 (3) 2
Duration of OC use
< 5 years 316 (24) 1,934 (23) 159 (20) 1
5 to 9 years 235 (18) 1,364 (17) 125 (16) 1
10 to 14 years 178 (14) 874 (11) 81 (11) 6
≥ 15 years 59 (4) 350 (4) 47 (6) 4
Data presented as n (%). Total percentages may not add up to 100% due to roundi
status. ER status was unknown for 1,151 breast cancer cases: 90 in CBCS, 308 in WC
and Risk; BWHS, Black Women’s Health Study; CBCS, Carolina Breast Cancer Study; E
Health Study.within the previous 5 years, 5 to 9 years ago, 10 to
14 years ago, 15 to 19 years ago, 20 to 24 years ago, 25
to 29 years ago, or ≥30 years ago. Duration of OC use
was categorized as 1 to 4 years, 5 to 9 years, 10 to
14 years, or ≥15 years.
Covariates
Self-reported data were available on the following cova-
riates: history of breast cancer in a first-degree female
relative (mother, sister, or daughter), age at menarche,
parity, age at first birth, lifetime duration of breastfee-
ding, menopausal status, age at menopause, menopausal
female hormone use, height, weight, educational attain-
ment, alcohol consumption, and cigarette smoking. For
menopausal status, women who were still menstruatingnsortium, by included study (BWHS, CBCS, WCHS)
WCHS Total
ontrols Cases Controls Cases Controls
774 2,891
550 (71) 1,848 (64)
224 (29) 1,043 (36)
129 (17) 494 (17)
87 (11) 324 (11)
209 (27) 856 (30)
277 (36) 923 (32)
191 (25) 788 (27)
87 (49) 374 (48) 477 (49) 1,291 (45) 4,632 (46)
98 (51) 400 (52) 492 (51) 1,600 (55) 5,412 (54)
2 (7) 64 (8) 73 (8) 314 (11) 1,075 (11)
2 (4) 36 (5) 48 (5) 148 (5) 544 (5)
9 (8) 39 (5) 37 (4) 169 (6) 595 (6)
5 (11) 45 (6) 52 (5) 245 (8) 757 (8)
02 (13) 47 (6) 65 (7) 245 (8) 859 (9)
6 (6) 55 (7) 79 (8) 214 (7) 778 (8)
1 (3) 108 (14) 130 (13) 256 (9) 795 (8)
74 (22) 152 (20) 207 (21) 627 (22) 2,315 (23)
23 (16) 121 (16) 142 (15) 481 (17) 1,629 (16)
1 (8) 71 (9) 75 (8) 330 (11) 1,010 (10)
0 (5) 56 (7) 68 (7) 162 (6) 458 (5)
ng. Excluding women with unknown duration of OC use and unknown ER
HS, and 753 in BWHS. AMBER, African American Breast Cancer Epidemiology
R, estrogen receptor; OC, oral contraceptive; WCHS, Women’s Circle of
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perienced a natural menopause or a hysterectomy with
bilateral oophorectomy were classified as postmeno-
pausal. Also classified as postmenopausal were women
(n = 60) whose periods had stopped due to use of me-
diation, radiation, or chemotherapy for various health
conditions other than breast cancer. Women who had a
hysterectomy with retention of one or both ovaries were
classified as premenopausal if their index age was less
than or equal to the age at which 10% of women in their
study had reached natural menopause, and as postmeno-
pausal if their index age was greater than or equal to the
age at which 90% of women in their study had reached
natural menopause; otherwise, these participants were
classified as having unknown menopausal status.
Data analysis
Polytomous logistic regression models were used to cal-
culate odds ratios (ORs) and 95% confidence intervals
(CIs) for the relation of measures of OC use to ER+ and
ER– breast cancer risk. For TN breast cancer risk, poly-
tomous models had three outcomes: TN, ER+, and
ER–/not TN. We controlled for age (continuous), study
(CBCS, WCHS, BWHS), time period of case diagnosis/
control index date (1993 to 1998, 1999 to 2005, 2006 to
2013), family history of breast cancer (yes, no), age at
menarche (<12, 12 to 13, ≥14 years), parity (0, 1, 2, ≥3
births), age at first birth (<20, 20 to 24, ≥25 years), lacta-
tion (never, ever), menopausal status and age at meno-
pause (premenopausal, <45, 45 to 49, 50 to 54, ≥55 years),
female hormone use (0, <5, ≥5 years of use), body mass
index (weight in kilograms divided by height in meters
squared; <18.5, 18.5 to 24.9, 25.0 to 29.9, 30.0 to
34.9, ≥35.0 kg/m2), educational attainment (<12, 12, 13 to
15, 16, >16 years), alcohol consumption (<1, 1 to 6, ≥7
drinks per week), smoking status (0, <10, 10 to 19, ≥20
pack-years), and geographic region (New Jersey, other
Northeast, South, Midwest, West). We used the missing
indicator method to handle missing data. For menopausal
status, 8.8% of women had missing data; for each of the
other covariates, fewer than 2% had missing data. To test
for trend across categories of OC duration or OC recency,
the ordinal variable was treated as a continuous variable
in the regression model. Trend tests were carried out
among OC users only. To examine potential differences
by subtype, we carried out case–case analyses, in which
ORs were computed for the relation of OC use to ER–
relative to ER+ breast cancer. Effect modification was ex-
plored through stratification by age, menopausal status,
body mass index, and parity. Interaction on the multi-
plicative scale was tested by the likelihood ratio test, com-
paring models with and without multiplicative interaction
terms. Analyses were performed using SAS 9.2 statistical
software (SAS Institute Inc., Cary, NC, USA).In addition to the main analyses, which were carried
out in pooled data, study-specific ORs were calculated
and combined in a random-effects meta-analysis. The
Cochran’s Q statistic was used to test for heterogeneity
[37]. Meta-analyses were performed using Stata/SE 11.2
statistical software (StataCorp LP, College Station, TX,
USA).
Results
Characteristics of cases and controls are presented in
Table 1. Among the 2,891 cases, 1,043 (36%) had tumors
that were classified as ER– and 1,848 (64%) were classi-
fied as ER+ (Table 1). In addition, 494 of the ER– cases
were TN breast cancer. The mean age at diagnosis was
52.7, with 11.2% of cases diagnosed before age 40 and
27.3% diagnosed at age 60 or older. OC use was similar
across the three participating studies.
Table 2 presents analyses of OC use in relation to ER+
and ER– breast cancer. Ever OC use was positively asso-
ciated with both ER+ (OR = 1.15, 95% CI = 1.02 to 1.28)
and ER– (OR = 1.24, 95% CI = 1.07 to 1.43) breast can-
cer. There was a significant dose–response association
with recency of OC use for both ER+ and ER– breast
cancer (P trend <0.01 and P trend = 0.05, respectively).
The strongest associations were for OC use within the
previous 5 years (OR = 1.46, 95% CI = 1.18 to 1.81 for
ER+ breast cancer and OR = 1.57, 95% CI = 1.22 to 2.03
for ER– breast cancer). For ER+ breast cancer, the ORs
were elevated through 15 to 19 years since last use and
the estimate for 15 to 19 years was statistically signifi-
cant (OR = 1.29, 95% CI = 1.04 to 1.58). For ER– breast
cancer, the pattern was less consistent; the OR declined to
1.07 (95% CI =, 0.83 to 1.37) at 20 to 24 years since last
use, but there was a statistically significant elevation at 25
to 29 years since last use (OR = 1.41, 95% CI = 1.09 to 1.81).
Risk of ER– cancer increased with increasing duration of
OC use, with ORs of 1.43 (95% CI = 1.13 to 1.80) and 1.54
(95% CI = 1.15 to 2.06) for 10 to 14 and ≥15 years dura-
tion, respectively. For ER+ breast cancer, the OR for 10 to
14 years duration was elevated (1.35, 95% CI = 1.12 to
1.61) but the estimate for ≥15 years was approximately
1.00. Among recent users, risk increased with increasing
duration of OC use for both ER+ and ER– cancer. The
OR for ≥10 years of use that continued into the 5 years
before diagnosis or index date was 1.65 (95% CI = 1.27 to
2.15) for ER+ cancer and 1.73 (95% CI = 1.26 to 2.37) for
ER– cancer. The corresponding estimates for ≥10 years of
use that ended at least 20 years previously was 0.88 (95%
CI = 0.65 to 1.19) for ER+ cancer and 1.50 (95% CI = 1.03
to 2.17) for ER– cancer.
In a case–case analysis (data not shown), ever use of
OCs (OR = 1.09, 95% CI = 0.92 to 1.29) and OC use
within the previous 5 years (OR = 1.08, 95% CI = 0.79 to
1.46) were not associated with ER– breast cancer,
Table 2 Oral contraceptive use in relation to ER+ and ER– breast cancera
ER+ ER–
Controls (n) Cases (n) OR (95% CI) Cases (n) OR (95% CI)
Never users 4,632 862 1.00 Reference 429 1.00 Reference
Ever users 5,415 990 1.15 (1.02 to 1.28) 615 1.24 (1.07 to 1.43)
OC recency
< 5 years ago 1,075 183 1.46 (1.18 to 1.81) 131 1.57 (1.22 to 2.03)
5 to 9 years ago 544 84 1.16 (0.89 to 1.52) 64 1.33 (0.97 to 1.82)
10 to 14 years ago 595 105 1.25 (0.98 to 1.60) 64 1.12 (0.82 to 1.52)
15 to 19 years ago 757 153 1.28 (1.04 to 1.58) 92 1.14 (0.88 to 1.48)
20 to 24 years ago 859 148 1.01 (0.82 to 1.24) 97 1.07 (0.83 to 1.37)
25 to 29 years ago 781 123 0.93 (0.75 to 1.15) 91 1.41 (1.09 to 1.81)
≥ 30 years ago 795 185 1.14 (0.94 to 1.38) 71 1.14 (0.85 to 1.51)
P trend <0.01 0.05
OC duration
< 5 years 2,315 367 1.03 (0.89 to 1.19) 260 1.21 (1.01 to 1.44)
5 to 9 years 1,629 321 1.25 (1.07 to 1.46) 160 1.07 (0.87 to 1.32)
10 to 14 years 1,010 209 1.35 (1.12 to 1.61) 121 1.43 (1.13 to 1.80)
≥ 15 years 458 89 0.98 (0.76 to 1.27) 73 1.54 (1.15 to 2.06)
P trend 0.13 0.05
Joint OC exposure (recency and duration)
Since last use Duration
< 5 years < 5 years 329 39 1.13 (0.78 to 1.62) 30 1.20 (0.78 to 1.83)
5 to 9 years 289 45 1.60 (1.12 to 2.28) 33 1.67 (1.10 to 2.53)
≥ 10 years 457 99 1.65 (1.27 to 2.15) 68 1.73 (1.26 to 2.37)
5 to 9 years < 5 years 172 22 1.21 (0.75 to 1.94) 16 1.26 (0.72 to 2.21)
5 to 9 years 140 30 1.62 (1.05 to 2.52) 13 0.94 (0.51 to 1.74)
≥ 10 years 232 32 0.92 (0.62 to 1.38) 35 1.59 (1.06 to 2.38)
10 to 19 years < 5 years 466 66 1.09 (0.82 to 1.47) 58 1.21 (0.87 to 1.67)
5 to 9 years 451 87 1.33 (1.02 to 1.73) 46 0.94 (0.66 to 1.33)
≥ 10 years 435 105 1.41 (1.11 to 1.81) 52 1.24 (0.90 to 1.72)
≥ 20 years < 5 years 1,344 238 1.02 (0.86 to 1.20) 155 1.23 (1.00 to 1.51)
5 to 9 years 748 157 1.13 (0.92 to 1.38) 65 1.00 (0.75 to 1.33)
≥ 10 years 340 61 0.88 (0.65 to 1.19) 39 1.50 (1.03 to 2.17)
CI, confidence interval; ER, estrogen receptor; OC, oral contraceptive; OR, odds ratio. aORs adjusted for age, study, time period, geographic region, education, age
at menarche, parity, age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone
use, body mass index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
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cancer was associated with long duration (≥15 years) of
OC use relative to ER+ cancer: the OR was 1.51 (95%
CI = 1.07 to 2.15).
In an analysis stratified by invasive and in situ breast
cancer (data not shown), results for invasive cancer
(1,150 ER+ and 629 ER– cases) were similar to the over-
all findings: the ORs for invasive ER+ cancer were 1.14
(95% CI = 1.00 to 1.31) for ever use, 1.41 (95% CI = 1.10
to 1.81) for use within the previous 5 years, and 0.95
(0.69 to 1.30) for duration of 15 years or more; thecorresponding estimates for invasive ER– cancer were
1.36 (95% CI = 1.14 to 1.62), 1.62 (95% CI = 1.20 to 2.20)
and 1.59 (1.11 to 2.29), respectively. For in situ cancer,
based on 255 ER+ cases, risk of ER+ breast cancer was
significantly elevated for recent OC use (OR = 1.66, 95%
CI = 1.02 to 2.68), but was not associated with long
duration of OC use (OR = 0.95, 95% CI = 0.51 to 1.75).
There were too few ER– in situ cases (n = 43) for an in-
formative analysis.
The relation of OC use to risk of TN breast cancer is
presented in Table 3. The OR for recent use of OCs
Table 3 Oral contraceptive use in relation to triple-negative breast cancera
Controls (n) Cases (n) OR (95% CI)
Never users 4,632 213 1.00 Reference
Ever users 5,415 282 1.14 (0.93 to 1.40)
OC recency
< 5 years ago 1,075 66 1.78 (1.25 to 2.53)
5 to 9 years ago 544 33 1.37 (0.88 to 2.12)
10 to 14 years ago 595 37 0.99 (0.63 to 1.56)
15 to 19 years ago 757 47 1.19 (0.83 to 1.72)
20 to 24 years ago 859 40 0.85 (0.89 to 1.24)
25 to 29 years ago 781 40 1.26 (0.87 to 1.81)
≥ 30 years ago 795 30 0.91 (0.59 to 1.38)
P trend 0.05
OC duration
< 5 years 2,315 117 1.08 (0.84 to 1.39)
5 to 9 years 1,629 73 0.99 (0.74 to 1.34)
10 to 14 years 1,010 51 1.26 (0.90 to 1.77)
≥ 15 years 458 40 1.62 (1.11 to 2.38)
P trend 0.05
Joint OC exposure
Since last use Duration
< 5 years < 5 years 329 14 1.31 (0.72 to 2.40)
5 to 9 years 289 21 2.70 (1.58 to 4.61)
≥ 10 years 457 30 1.66 (1.06 to 2.60)
5 to 9 years < 5 years 172 5 0.89 (0.35 to 2.30)
5 to 9 years 140 7 1.08 (0.47 to 2.48)
≥ 10 years 232 19 1.79 (1.04 to 3.07)
10 to 19 years < 5 years 466 26 1.12 (0.70 to 1.79)
5 to 9 years 451 21 0.87 (0.53 to 1.45)
≥ 10 years 435 27 1.36 (0.87 to 2.11)
≥ 20 years < 5 years 1,344 72 1.11 (0.83 to 1.49)
5 to 9 years 748 22 0.67 (0.42 to 1.06)
≥ 10 years 340 15 1.14 (0.65 to 2.00)
CI, confidence interval; OC, oral contraceptive; OR, odds ratio. aORs adjusted for age, study, time period, geographic region, education, age at menarche, parity,
age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass
index, alcohol consumption, and pack-years of cigarette smoking. P trend does not include never users.
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and risk declined as the interval since last use increased
(P trend =0.05). Risk increased with increasing duration
of OC use, with an OR of 1.62 (95% CI = 1.11 to 2.38)
for ≥15 years of use (P trend = 0.05). Analyses of a joint
variable for duration and recency of use indicated that
the increased risk associated with at least 10 years of OC
use was statistically significant both for use less than
5 years ago (OR = 1.66, 95% CI = 1.06 to 2.00) and use 5
to 9 years ago (OR = 1.79, 95% CI = 1.04 to 3.07).
In analyses stratified by age (<40 years, 40 to
49 years, ≥50 years), recent and long-duration OCuse were associated with increased risk of breast cancer
in every age group (Table 4). The interaction was not
statistically significant for OC recency or duration
(P interaction = 0.75 and P interaction = 0.77, respectively).
In analyses stratified by menopausal status (Table 5),
ORs were higher in premenopausal women, but there was
not a statistically significant interaction (P interaction =
0.16 for recency, P interaction = 0.06 for duration). Breast
cancer risk was elevated for recent OC use in both nul-
liparous and parous women (Table 5): among nulliparous
women the OR for OC use within the previous 5 years
was 1.37 (95% CI = 0.98 to 1.92), and the corresponding
Table 4 Oral contraceptive use in relation to breast cancer risk, stratified by agea
Age <40 Age 40 to 49 Age ≥50
Controls (n) Cases (n) OR (95% CI) Controls (n) Cases (n) OR (95% CI) Controls (n) Cases (n) OR (95% CI)
Never users 351 85 1.00 Reference 1,022 272 1.00 Reference 3,259 934 1.00 Reference
Ever users 796 239 1.33 (0.97 to 1.81) 2,057 584 1.18 (0.98 to 1.42) 2,562 782 1.15 (1.01 to 1.30)
OC recency
< 5 years ago 482 130 1.55 (1.09 to 2.19) 482 149 1.60 (1.23 to 2.07) 111 35 1.50 (0.99 to 2.28)
5 to 9 years ago 185 53 1.20 (0.77 to 1.86) 292 74 1.18 (0.86 to 1.63) 94 21 0.95 (0.57 to 1.58)
≥ 10 years ago 154 56 1.04 (0.67 to 1.61) 1,282 361 1.07 (0.88 to 1.31) 2,351 716 1.14 (1.00 to 1.29)
P trend 0.02 <0.01 0.45
OC duration
< 5 years 342 84 1.18 (0.81 to 1.70) 835 225 1.12 (0.90 to 1.40) 1,138 318 1.08 (0.92 to 1.27)
5 to 9 years 239 79 1.40 (0.95 to 2.06) 629 160 1.06 (0.83 to 1.35) 761 242 1.20 (1.00 to 1.44)
≥ 10 years 215 76 1.48 (0.99 to 2.20) 593 199 1.39 (1.10 to 1.76) 660 217 1.20 (0.99 to 1.45)
P trend 0.17 0.11 0.26
CI, confidence interval; OC, oral contraceptive; OR, odds ratio. aORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation, first-degree family history of











Table 5 Oral contraceptive use in relation to breast cancer risk, stratified by menopausal status and paritya
Controls (n) Cases (n) OR (95% CI) Controls (n) Cases (n) OR (95% CI)
Premenopausal women Postmenopausal women
Never users 1,371 363 1.00 Reference 2,903 854 1.00 Reference
Ever users 2,667 767 1.24 (1.05 to 1.45) 2,184 703 1.16 (1.01 to 1.33)
OC recency
< 5 years ago 937 273 1.54 (1.25 to 1.90) 90 19 1.02 (0.59 to 1.76)
5 to 9 years ago 404 113 1.31 (1.01 to 1.72) 99 21 0.85 (0.50 to 1.44)
≥ 10 years ago 1,324 380 1.08 (0.90 to 1.30) 1,989 654 1.17 (1.02 to 1.34)
P trend <0.01 0.39
OC duration
< 5 years 1,066 276 1.11 (0.91 to 1.35) 992 301 1.14 (0.96 to 1.36)
5 to 9 years 818 217 1.14 (0.92 to 1.41) 648 222 1.24 (1.02 to 1.50)
≥ 10 years 782 274 1.53 (1.25 to 1.88) 542 175 1.09 (0.88 to 1.34)
P trend <0.01 0.83
Nulliparous women Parous women
Never users 917 244 1.00 Reference 3,706 1,046 1.00 Reference
Ever users 1,230 267 1.09 (0.87 to 1.38) 4,183 1,338 1.21 (1.08 to 1.35)
OC recency
< 5 years ago 406 93 1.37 (0.98 to 1.92) 669 211 1.55 (1.26 to 1.90)
5 to 9 years ago 160 22 0.77 (0.46 to 1.29) 383 126 1.39 (1.08 to 1.77)
≥ 10 years ago 663 151 1.05 (0.81 to 1.36) 3,123 982 1.15 (1.03 to 1.29)
P trend 0.16 <0.01
OC duration
< 5 years 438 89 1.06 (0.79 to 1.44) 1,875 538 1.11 (0.97 to 1.27)
5 to 9 years 361 76 1.08 (0.78 to 1.50) 1,268 405 1.22 (1.05 to 1.42)
≥ 10 years 431 102 1.13 (0.84 to 1.52) 1,037 390 1.37 (1.17 to 1.60)
P trend 0.61 0.01
CI, confidence interval; OC, oral contraceptive; OR, odds ratio. aORs adjusted for age, study, time period, geographic region, education, age at menarche, parity,
age at first birth, lactation, first-degree family history of breast cancer, menopausal status and age at menopause, duration of female hormone use, body mass
index, alcohol consumption, and pack-years of cigarette smoking, where appropriate. P trend does not include never users. Women who were missing menopausal
status (n = 1,218) were excluded from the analysis that stratified on this variable. Women who were missing parity (n = 13) were excluded from the analysis that
stratified on this variable.
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(P interaction = 0.08). Long duration of OC use was asso-
ciated with breast cancer among parous women, but not
among nulliparous women (Table 5). The interaction was
not significant (P = 0.42).
Recent and long-duration OC use were associated with
larger increases in breast cancer risk among women who
were overweight or obese than among women with body
mass index <25 kg/m2 (Table 6). The interaction was
significant for recent OC use (P interaction = 0.04), but
not for duration of OC use (P interaction = 0.16).
Figure 1 presents study-specific estimates and ORs
for recent (within previous 5 years) and long-term
(≥10 years) OC use in relation to ER+ and ER– breast
cancer computed from a meta-analysis with a random-
effects model. The P value for heterogeneity was 0.57 orgreater for all comparisons, indicating no statistically
significant heterogeneity.
Discussion
Both recent OC use and long duration of OC use were
associated with increased risk of breast cancer in this
study of African American women. The positive asso-
ciations were observed for ER+, ER–, and TN breast
cancer. ORs were highest for TN breast cancer: women
who had used OCs in the past 5 years were estimated to
have a 78% increased risk of TN breast cancer and those
who had used OCs for at least 15 years had a 62%
increase.
While some studies have found no association of re-
cent OC use with overall breast cancer risk [2,3,5,38,39],
many others have reported that recent OC users
Table 6 Oral contraceptive use in relation to breast cancer risk, stratified by body mass indexa
BMI <25.0 kg/m2 BMI 25.0 to 29.9 kg/m2 BMI ≥30.0 kg/m2
Controls (n) Cases (n) OR (95% CI) Controls (n) Cases (n) OR (95% CI) Controls (n) Cases (n) OR (95% CI)
Never users 931 231 1.00 Reference 1,503 387 1.00 Reference 2,096 637 1.00 Reference
Ever users 1,371 350 1.09 (0.88 to 1.35) 1,746 521 1.13 (0.95 to 1.35) 2,211 707 1.26 (1.09 to 1.45)
OC recency
< 5 years ago 361 87 1.22 (0.87 to 1.71) 320 111 1.58 (1.16 to 2.14) 377 112 1.57 (1.19 to 2.08)
5 to 9 years ago 156 32 0.87 (0.55 to 1.38) 175 46 1.06 (0.71 to 1.58) 204 69 1.71 (1.23 to 2.37)
≥ 10 years ago 851 230 1.09 (0.87 to 1.38) 1,248 363 1.09 (0.90 to 1.31) 1,627 518 1.17 (1.01 to 1.36)
P trend 0.17 0.05 0.04
OC duration
< 5 years 566 135 1.05 (0.80 to 1.37) 726 198 1.12 (0.90 to 1.39) 986 278 1.09 (0.91 to 1.30)
5 to 9 years 408 109 1.11 (0.83 to 1.49) 544 152 1.04 (0.82 to 1.33) 651 213 1.34 (1.09 to 1.64)
≥ 10 years 397 105 1.11 (0.83 to 1.50) 476 171 1.27 (1.00 to 1.61) 571 212 1.48 (1.20 to 1.82)
P trend 0.67 0.48 <0.01
BMI, body mass index; CI, confidence interval; OC, oral contraceptive; OR, odds ratio. aORs adjusted for age, study, time period, geographic region, education, age at menarche, parity, age at first birth, lactation,












Figure 1 Results from meta-analysis of oral contraceptive recency and duration in relation to breast cancer subtype. Odds ratios and
95% confidence intervals from the full model by study and from a random-effects meta-analysis for oral contraceptive (OC) recency in relation to
ER+ (A) and ER– (B) breast cancer and OC duration in relation to ER+ (C) and ER– (D) breast cancer. BWHS, Black Women’s Health Study; CBCS,
Carolina Breast Cancer Study; ER, estrogen receptor; WCHS, Women’s Circle of Health Study.
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24% to 60% [1,6,9,11,12,40]. The present findings are
similar in magnitude to the previous positive associa-
tions. A collaborative analysis of 54 studies concluded
that the increased risk of breast cancer associated with
OC use disappears by 10 years after last use [1]. In a
large case–control study that included African American
women, no association was observed for long intervals
(≥20 years) since last OC use [2,3]. However, in the
present study of African American women, an increased
risk was present up to 15 to 19 years after last use for
ER+ cancer and after an even longer interval for ER–
cancer. Results for duration of use are less consistent in
the literature, with some studies reporting no association
with long duration [2,3,25,39,41-43] while others ob-
served a positive association [4-13]. In the present study,
long duration use appeared to be more strongly asso-
ciated with ER– cancer than with ER+ cancer.
There are few previous studies of OC use with molecu-
lar subtype of breast cancer. Five studies found associa-
tions of OC use with both ER+ and ER– breast cancer
[4,8-10,12]. One study found an association for only ER+
breast cancer [24] and two found an association for onlyER– breast cancer [23,44], while two other studies found
no association for either subtype [45,46]. Of the studies
that could evaluate TN or basal-like breast cancer, three
found a positive association [10,23,26,47] while two others
observed no association [2,25].
Combination OCs contain estrogens and progestins
and have been found to increase circulating levels of
estradiol [48,49]. A potential mechanism for increased
risk of breast cancer with recent OC use is through
estrogen-induced or progesterone-induced proliferation
of breast cancer cells [50,51], which could cause pro-
gression of breast cancer. This mechanism may not be
applicable for ER– breast cancer. Estrogens may also
promote angiogenesis and stromal cell recruitment [52],
which would be relevant for both ER+ and ER– breast
cancer. OCs may also cause epigenetic changes, such as a
decrease in DNA methylation [53]. DNA hypomethylation
may be associated with tumor progression and metastasis
[54] and represents another potential mechanism for the
relation of OC use to breast cancer risk. It has been
suggested that tumors regress after cessation of use of
menopausal hormone supplements [55,56]. The tumors
associated with menopausal hormone use are ER+.
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use is unknown, but this mechanism might not explain re-
sults for ER– breast cancer.
Few studies have examined potential effect modifica-
tion of the relation of OC use to breast cancer risk by
age [9,23,57]. Of these, some studies have observed a
stronger association with risk among younger women
than among older women, but this difference has gene-
rally not been statistically significant [4,26,58,59]. In a
report from the BWHS, age did not significantly modify
the association of OC use with breast cancer subtype
[9]. In a Washington state case–control study, ORs for
OC use were higher among women under age 40, but
there was not a significant interaction by age [23]. In a
multisite case–control study, ORs for OC use were signifi-
cantly higher among women under age 35 and age 35 to
44 years, compared with women age 45 years and older
[57]. In the present study, ORs were somewhat higher in
the youngest age group, but there was not a significant
interaction. ORs were also higher among premenopausal
women than among postmenopausal women, but, again,
the interaction was not statistically significant and there
were few recent users among the postmenopausal women.
Previous studies have observed associations of OC use
with breast cancer risk in both premenopausal and post-
menopausal women [8,45].
Differences in risk of breast cancer by age or meno-
pausal status could reflect changes in OC formulations.
The estrogen and progestin composition of OCs has
varied, with declining doses of hormones and new types
of progestin introduced over time [40,60,61]. There is no
clear evidence that some formulations carry higher risk
than others [5,62-64]. We were not able to evaluate for-
mulation, as we did not have detailed information on
OC type used. Thus, we cannot rule out the possibility
that associations vary according to OC formulation.
However, while younger women are more likely to use
newer OC formulations, our findings did not vary sig-
nificantly by strata of age or birth cohort in the present
study. Moreover, estimates were similar across the stu-
dies, which were conducted in different time frames ran-
ging from 1993 to present.
The associations of OC use with breast cancer risk in
the present study were stronger among overweight and
obese women. No previous studies have assessed whether
an association of breast cancer risk with recent or long
duration of OC use is modified by body mass index. This
finding is particularly important given the high prevalence
of obesity in African American women [65]. Obesity may
alter the pharmacokinetic parameters of OCs, which could
prolong exposure to estrogen in obese women due to an
increase in the half-life of circulating estradiol, an increase
in the rate of OC absorption, or an increase in bioavail-
ability of the chemical compounds in the OCs [66-68].The present analysis is the largest yet conducted of
OC use in relation to specific subtypes of breast cancer
among African American women. It allowed for infor-
mative assessment of associations within subtype overall
and within some strata of interest. However, statistical
power in some subanalyses was limited. Numerous im-
portant risk factors for breast cancer were controlled in
the analyses. While the studies that contributed to the
present analyses differed in study design and in popula-
tion characteristics, a meta-analysis found no significant
heterogeneity in the results. In addition, results on other
risk factors, including parity and body size, have been
similar across the individual studies [8,21,69-72]. Thus,
the results are likely to be generalizable to other African
American women. A limitation was that the classifica-
tion by molecular subtype was based on the particular
methods used in each pathology laboratory in the large
number of hospitals from which the cases were derived.
However, it is unlikely that misclassification will have
been related to the OC use of cases. We did not have
data to validate self-reported OC use, but validation
studies have shown that OC use is generally well re-
ported [5,73,74]. We did not have detailed information
on OC type used, and therefore cannot rule out varia-
tions in associations by OC formulation.
Conclusions
In sum, our findings suggest that recent OC use, par-
ticularly of long duration, is associated with increased
risk of ER+, ER–, and TN breast cancer in African
American women, with possibly a stronger relation with
TN breast cancer. Increases in risk associated with OC
use were apparent for up to 15 years or more after ces-
sation of use. The association with OC use was most
pronounced among overweight and obese women. Re-
search is needed to investigate the mechanisms by which
obesity may further increase the breast cancer risk asso-
ciated with OC use.
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